Longeveron Inc

LGVN

Company Profile

  • Business description

    Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.

  • Contact

    1951 NW 7th Avenue
    Suite 520
    MiamiFL33136
    USA

    T: +1 305 909-0840

    https://www.longeveron.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    38

Stocks News & Analysis

stocks

Investors punish this ASX player after acquisition

We think the floundering stock price is not reflective of underlying asset value.
stocks

Revenue growth on track for undervalued ASX healthcare stock

Near-term cost growth does not change our long-term view.
stocks

Sales shine but broader macro outlook darkens for this ASX share

US stores are struggling, but our investment thesis hinges on the Australian rollout.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,155.8034.000.37%
CAC 408,259.6013.810.17%
DAX 4023,803.953.04-0.01%
Dow JONES (US)47,916.57269.23-0.56%
FTSE 10010,600.532.95-0.03%
HKSE25,893.54141.140.55%
NASDAQ22,902.8980.480.35%
Nikkei 22556,924.111,028.791.84%
NZX 50 Index13,181.4492.37-0.70%
S&P 5006,816.897.77-0.11%
S&P/ASX 2008,960.6036.200.41%
SSE Composite Index3,986.2220.050.51%

Market Movers